The 11th edition of iPHEX 2025 will be held on September 4–5, 2025 at Bharat Mandapam, New Delhi, reaffirming India’s position as the “Pharmacy of the World.”

Organized by Pharmexcil with support from the Government of India, the platform brings together regulators, policymakers, and industry leaders from across the globe. This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings, positioning iPHEX as one of the most business-driven exhibitions globally.

Key highlights of iPHEX 2025 include: Global Regulatory Conclave (in collaboration with CDSCO, Ministry of Health & Family Welfare), a knowledge-sharing platform to enhance international regulatory cooperation and promote global recognition of Indian Pharmacopoeia.

The Global Regulatory Conclaves will address critical themes that directly influence Indian pharma’s competitiveness and global positioning: Access to Quality Medicines through Regulatory Convergence and Reliance – Reducing duplication, enabling faster approvals, and lowering costs; Good Reliance Practices (GRPs) – Regulatory reliance as a lever for affordable and timely market entry; Bharat Health Vision 2030 & 2047 – Aligning India’s long-term health roadmap with global trade ambitions; Market Access to Highly Regulated Markets – Strategies for the US, EU, and Japan, where Indian pharma faces the tightest scrutiny; RoW Market Opportunities – Expanding footprints in Africa, Latin America, and ASEAN to offset concentration risks; and Pharmacopoeia Convergence (BP, IP, and USP) – Standard harmonisation as a tool for building trust in Indian-made generics.

The conclaves underscore the sector’s growing influence in both advanced economies and emerging markets. This offers a vantage point into how India’s regulatory roadmap, market access strategies, and export leadership are shaping the future of global healthcare.

Bhavin Mehta, Vice Chairman, Pharmexcil and Chairman of iPHEX 2025 said, “iPHEX 2025 is more than a trade platform—it is a dialogue on India’s responsibility as the Pharmacy of the World. The 10th edition (2024) of iPHEX had recorded 7,400 meetings. The 11th edition (2025) is set to surpass this benchmark with close to 8,400 meetings — reflecting the event’s scale and rising global traction. Through the Global Regulatory Conclaves, we aim to harmonize standards, build global trust in Indian generics, and accelerate access to affordable medicines. This is where India’s regulatory vision meets the world’s healthcare priorities.”

The Indian Pharmacopoeia (IP) will be a key focus at iPHEX 2025, with an emphasis on showcasing its global recognition, efficacy, and cost advantage. “Our focus this year is to champion the Indian Pharmacopoeia and reaffirm its global relevance. Already, 12 countries have recognized and accepted the Indian Pharmacopoeia, and in 2025 our goal is to bring another 10–12 nations on board—further strengthening India’s position as a trusted, accessible, and globally aligned healthcare partner,” added Mehta.

At its core, iPHEX 2025 Powers Healthcare and Connects Markets—serving as a convergence platform where India’s pharmaceutical leadership meets the world’s healthcare future.